Hoss Why I think FRTD should be part of your investment strategy.
Fortitude Group Inc. is now under the direction of Thomas Parilla. This once beaten and battered shell finally has a CEO and management team that is up to the task of building a real viable company. FRTD recently acquired Legacy Life Science (L2S).
The L2S premium product portfolio contains the Comprehensive Airway Management System consisting of five, patented FDA approved products ready for worldwide distribution and sales. The Comprehensive Airway Management System is engineered to significantly reduce and prevent respiratory distress in the perioperative procedural sedation environment (anesthesia). A common scenario in peri-operative procedural sedation involves degradation of patient airway monitoring and management; and therefore, constitutes the designation as a Hospital Acquired Condition or (HAC) for respiratory related distress.
The company is best described as:
Fortitude Group Inc. develops practical solutions for healthcare with direct holdings, subsidiaries and or joint ventures. The Company’s service-product portfolio includes premium FDA approved medical devices and advanced technologies engineered to prevent the risk associated healthcare acquired conditions and improve clinical outcomes.
--------------------------------------------------------------------------------
FRTD as you will soon realize is not your typical penny stock. Just look at the bio’s of the company’s management team:
Thomas Parilla - CEO
VP Regional Manager of Brokerage operations for NW Pennsylvania
1st National Bank Investments
December 1999 – December 2002 (3 years 1 month)
VP Regional Manager of all Brokerage Operations in NW PA.
Honors & Awards
National City Bank Chairman's Conference Award
National City Bank
1998
Highest Brokerage Award at National City Bank
Chairman's Conference Award at First National Bank
2000
Highest Brokerage Award at First National Bank
3 Time Winner of the Putnam Funds Golden Scale Council
Putnam Funds
Highest Award for Sales and Client Service from Putnam Mutual Funds
3 Time Winner of the American Funds - All American Team
American Funds
Highest Award for Sales and Client service by The American Funds
Federated Funds - President's Achievement Club
Federated Funds
Highest Award for Sales and Client Service by Federated Funds
Van Kampen Funds - Generations of Experience Club
Van Kampen Funds
Highest award for Sales and Client Service by The Van Kampen Funds
National City Bank - Rookie of the Year Award
National City Bank
Awarded as the top 1st year Broker in the Northwest Pennsylvania Region
Christopher J. Cuzzola President - received a M.Ed. in Administrative Leadership, Learning Theory, and Design from Edinboro University and a B.A. from Mercyhurst University. Cuzzola brings a history of exceptional performance applying his entrepreneurial skills to the challenging life science medical device industry.
During his career with Pfizer, Chris was a consistent high achiever while earning several top specialty and hospital sales performance awards, including a number one ranking as national sales representative of the year. Cuzzola has extensive training in various disease states including infectious diseases. In addition to family and professional passions, Chris remains dedicated to causes associated with advancing education and research.
Dr. Anthony J Colantonio - Chief Technology Officer - Dr. Colantonio completed fellowship training in Interventional Pain Medicine at the Oregon Health and Science University, residency training at Duke University in Anesthesiology, and medical and undergraduate education at Georgetown University and is a Diplomat of the American Board of Anesthesiology and the American Academy of Pain Management. Dr. Colantonio is the Director of the Clinic for Specialty Pain Services at Meadville Medical Center, with a clinical focus upon neuromodulation therapy and geriatric care. Dr. Colantonio is a regional key opinion leader for numerous pharmaceutical and medical device companies and a national speaker for Pfizer Pharmaceuticals.
As a clinician-inventor, Colantonio is a tireless advocate for patients and medical providers and has dedicated his entrepreneurial career to identifying critical healthcare problems and solving them with innovative products and services. Anthony holds two utility patents through the USPTO and six patents pending. As the Chief Medical Officer of the Life Science Division, Dr. Colantonio leads the research and development efforts from initial product design to bench-top testing, clinical trials, and final product validation through the company’s regulatory and quality efforts. Dr. Colantonio plays a critical role in the development of professional partnerships with leading healthcare institutions, and key opinion leaders in the fields of anesthesia, interventional pain management, and infection prevention services with specific emphasis upon the reduction of healthcare acquired conditions (HACs). "
Given the sad history of this shell prior to the new management and the new field of endeavor undertaken, it is understandable that some may be hesitant to take a position. But while some sit on the sidelines, others are accumulating all they can of this dynamic company, while the PPS is still cheap.
It is true that the new CEO has his work cut out for him, giving the past mismanagement and uncaring displayed towards shareholders, as one convertible after another has pounded this stock under the old management. That has all changed, the printing press has stopped. And as new investors step up it is plain to see that the flow of stock being sold into the market has slowed. Once this company starts releasing expected news, the PPS will rise.
Now would be a good time for you to take one more good look at FRTD.
Didn't do your
DD, did you !
